This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ChemoCentryx (CCXI) Tavneos Gets FDA Nod for ANCA Vasculitis
by Zacks Equity Research
The FDA approves ChemoCentryx's (CCXI) lead drug Tavneos to treat ANCA-associated vasculitis. It is the company's first drug to get FDA approval. Resultantly, the stock gains in pre-market trading.
Amgen (AMGN) Reports New Data From Lumakras Combo Study
by Zacks Equity Research
Amgen (AMGN) reports new combination data from the phase Ib CodeBreaK 101 study. It also buys a stake in Neumora Therapeutics to advance novel therapies for brain diseases.
4D Molecular (FDMT) to Start Studies on Cystic Fibrosis, Wet AMD
by Zacks Equity Research
4D Molecular (FDMT) is set to initiate studies for gene-therapy candidates to treat cystic fibrosis lung disease and wet AMD, following FDA clearance of its two IND applications.
Acer's (ACER) NDA for ACER-001 in UCD Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts Acer's (ACER) NDA for ACER-001 (sodium phenylbutyrate) for the treatment of patients with urea cycle disorders. A decision is due on Jun 5, 2022. Stock up.
Here's Why You Should Hold on to Illumina (ILMN) for Now
by Zacks Equity Research
Investors are optimistic about Illumina (ILMN) owing to its strategic partnerships and wider market adoption of its products.
Abbott (ABT) Gets FDA Nod for Amplatzer Talisman System
by Zacks Equity Research
The Amplatzer Talisman PFO Occlusion System from Abbott (ABT) is used to treat patients with a patent foramen ovale and are at risk of recurrent ischemic stroke.
Here's Why You Should Retain Myriad Genetics (MYGN) for Now
by Zacks Equity Research
Investors are optimistic about Myriad Genetics (MYGN) owing to strong testing volume growth and notable product launches.
Alcon's (ALC) Robust Product Line, Market Rebound Aid Growth
by Zacks Equity Research
In Presbyopia-correcting Intraocular Lens (PCIOLs), Alcon (ALC) currently leads the market with over 55% of global share and over 80% share in the United States.
Amcius (FOLD) to Spin-Off Gene Therapy Arm, Form New Firm With ARYA
by Zacks Equity Research
Amicus (FOLD) plans to separate its gene therapy business into a new company formed in alliance with ARYA Sciences Acquisition Corp.
Regeneron's (REGN) sBLA for Libtayo Gets Priority Review
by Zacks Equity Research
Regeneron's (REGN) application seeking the label expansion of PD-1 inhibitor Libtayo for the treatment of patients with recurrent or metastatic cervical cancer has been granted Priority Review.
4 Top Biotech Stocks to Watch as Economic Recovery Picks Up Pace
by Ekta Bagri
New drug approvals and focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position REGN, MRNA, VRTX, and HZNP well amid the economic recovery.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Aerie (AERI) Announces Mixed Data From Dry Eye Disease Study
by Zacks Equity Research
Aerie Pharmaceuticals (AERI) reports mixed data from the phase IIb study evaluating AR-15512 for treating dry eye disease. Resultantly, the stock declines in after-market trading on Sep 15.
Here's Why You Should Retain QIAGEN (QGEN) Stock For Now
by Zacks Equity Research
Investors are optimistic about QIAGEN (QGEN) owing to impressive sales of diagnostic solutions and strong international growth.
3 Reasons Why Horizon Therapeutics (HZNP) Is a Great Growth Stock
by Zacks Equity Research
Horizon Therapeutics (HZNP) could produce exceptional returns because of its solid growth attributes.
Is Horizon (HZNP) a Great Growth Stock?
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Horizon (HZNP).
Horizon (HZNP) Begins Phase IV Study on Tepezza for Chronic TED
by Zacks Equity Research
Horizon (HZNP) enrolls the first patient in a phase IV study evaluating the safety and efficacy of Tepezza for the treatment of chronic (inactive) thyroid eye disease.
Here's Why Momentum Investors Will Love Horizon Therapeutics (HZNP)
by Zacks Equity Research
Does Horizon Therapeutics (HZNP) have what it takes to be a top stock pick for momentum investors? Let's find out.
Why Is Horizon Therapeutics (HZNP) Up 3.7% Since Last Earnings Report?
by Zacks Equity Research
Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Techne (TECH) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Techne (TECH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Anixa (ANIX) Ovarian Cancer CAR-T Drug to Enter Clinical Study
by Zacks Equity Research
The FDA clears Anixa Biosciences' (ANIX) application to initiate clinical studies for its ovarian cancer CAR-T therapy. The stock rises following the announcement.
BioMarin's (BMRN) Dwarfism Drug Gets Approval in Europe
by Zacks Equity Research
Biomarin Pharmaceutical's (BMRN) Voxzogo is the first medicine in Europe to be approved to treat achondroplasia, the most common form of dwarfism.
AstraZeneca's (AZN) Rare Disease Study Meets Primary Goal
by Zacks Equity Research
AstraZeneca's (AZN) phase III study evaluating ALXN1840 for Wilson disease achieves primary endpoint. The company also receives approval in Japan for Forxiga to treat chronic kidney disease.
Regeneron's (REGN) Wet AMD Study on High Dose Eylea Meets Goal
by Zacks Equity Research
Regeneron's (REGN) phase II study evaluating a higher 8-mg dose of Eylea injection in patients with wet age-related macular degeneration has met the primary safety endpoint.
Novartis (NVS) Kymriah Misses Primary Endpoint in NHL Study
by Zacks Equity Research
Novartis' (NVS) phase III study evaluating Kymriah for second-line treatment of patients with aggressive B-cell NHL fails to achieve primary endpoint of the study.